Consensus Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 00:00:02 14/02/2026 +03			5-day change	1st Jan Change
243.45 ^USD	-0.45%		+1.44%	+17.64%

02-13	Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial	RE
02-13	Pennsylvania jury finds Johnson & Johnson liable for woman's ovarian cancer - attorney for national talc plaintiffs	RE

Evolution of the Average Target: Johnson & Johnson

Evolution of the Target Price: Johnson & Johnson

Changes in Analyst Recommendations: Johnson & Johnson

f24b5f1aa0b12.LGkm6GLLZToESDHcHkaaXzTrsltpGtro-xoSADZk82Q.RFxAkjisDXgzG3qvKjPfGlqu2x0ia7eNjU5bQV8Gmj5HURO8KfwrWE54aA~090a4526f70aa8871af053e056833d4a

Analysts' recommendations: Johnson & Johnson

02-03	Johnson & Johnson's Solid Financial Position to Mitigate Talc Litigation Risk, RBC Says	MT
02-03	RBC Raises Price Target on Johnson & Johnson to $255 From $240, Keeps Outperform Rating	MT
01-30	HSBC Adjusts Johnson & Johnson PT to $265 From $240, Maintains Buy Rating	MT
01-29	Daiwa Securities Adjusts Price Target on Johnson & Johnson to $237 From $203, Maintains Outperform Rating	MT
01-28	Morgan Stanley Upgrades Johnson & Johnson to Overweight From Equalweight, Adjusts PT to $262 From $200	MT
01-23	Argus Raises Price Target on Johnson & Johnson to $240 From $210	MT
01-23	Bernstein Adjusts Price Target on Johnson & Johnson to $225 From $208, Maintains Market Perform Rating	MT
01-23	Guggenheim Adjusts Price Target on Johnson & Johnson to $240 From $227, Maintains Buy Rating	MT
01-22	Johnson & Johnson Reports Modest Q4 Beat but Stock Seems Fairly Valued, Morgan Stanley Says	MT
01-22	Goldman Sachs Adjusts Price Target on Johnson & Johnson to $250 From $240, Maintains Buy Rating	MT
01-22	Leerink Partners Adjusts Price Target on Johnson & Johnson to $232 From $201, Maintains Market Perform Rating	MT
01-22	Raymond James Adjusts Price Target on Johnson & Johnson to $237 From $209, Maintains Outperform Rating	MT
01-22	Wolfe Research Adjusts Price Target on Johnson & Johnson to $260 From $240, Maintains Outperform Rating	MT
01-22	Scotiabank Adjusts Price Target on Johnson & Johnson to $265 From $230, Maintains Sector Outperform Rating	MT
01-22	Stifel Adjusts Price Target on Johnson & Johnson to $220 From $205, Maintains Hold Rating	MT
01-22	JPMorgan Adjusts Price Target on Johnson & Johnson to $225 From $205, Maintains Neutral Rating	MT
01-22	Citigroup Adjusts Price Target on Johnson & Johnson to $250 From $232, Maintains Buy Rating	MT
01-22	TD Cowen Adjusts Price Target on Johnson & Johnson to $250 From $222, Maintains Buy Rating	MT
01-22	Morgan Stanley Adjusts Price Target on Johnson & Johnson to $200 From $197, Maintains Equalweight Rating	MT
01-22	Wells Fargo Adjusts Price Target on Johnson & Johnson to $240 From $230, Maintains Overweight Rating	MT
01-22	Morgan Stanley Raises Price Target on Johnson & Johnson to $200 From $197, Keeps Equalweight Rating	MT
01-09	Bernstein Adjusts PT on Johnson & Johnson to $208 From $193, Maintains Market Perform Rating	MT
01-07	Stifel Adjusts Price Target on Johnson & Johnson to $205 From $190, Maintains Hold Rating	MT
01-05	Wolfe Research Adjusts PT on Johnson & Johnson to $240 From $225, Maintains Outperform Rating	MT
12-30	Barclays Adjusts PT on Johnson & Johnson to $217 From $197, Maintains Equalweight Rating	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

243.45USD

Average target price

231.25USD

Spread / Average Target

-5.01%

High Price Target

265.00USD

Spread / Highest target

+8.85%

Low Price Target

155.00USD

Spread / Lowest Target

-36.33%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
HSBC
Daiwa Securities
Morgan Stanley
Argus
Bernstein
Guggenheim
Wells Fargo Securities
TD Cowen
Citigroup
JPMorgan Chase
Stifel Nicolaus
Scotiabank
Wolfe Research
Raymond James
Leerink Partners
Goldman Sachs
Barclays
Rothschild & Co Redburn
BofA Securities
UBS
DBS Bank
Redburn Atlantic
DZ Bank
Atlantic Equities
Credit Suisse
SVB Securities LLC
DA Davidson
SVB Financial
Sanford Bernstein
Cantor Fitzgerald
J.P. Morgan Chase
Cowen
SVB Leerink
RBC	Brandon Henry